Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia

J Antimicrob Chemother. 2015 Jan;70(1):311-3. doi: 10.1093/jac/dku322. Epub 2014 Aug 13.

Authors

Katie E Barber¹, Michael J Rybak², George Sakoulas³

Affiliations

¹ Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
² Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA School of Medicine, Wayne State University, Detroit, MI, USA.
³ Center for Immunity, Infection & Inflammation, University of California San Diego School of Medicine, La Jolla, CA, USA [email protected].

PMID: 25125677
DOI: 10.1093/jac/dku322

No abstract available

Keywords: combination therapy; haemodialysis; septic thrombophlebitis.

Publication types

Case Reports
Letter

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Bacteremia / drug therapy*
Bacteremia / microbiology
Ceftaroline
Cephalosporins / pharmacology
Cephalosporins / therapeutic use*
Daptomycin / pharmacology
Daptomycin / therapeutic use
Drug Resistance, Bacterial
Drug Synergism*
Drug Therapy, Combination / methods
Humans
Male
Methicillin-Resistant Staphylococcus aureus / drug effects*
Methicillin-Resistant Staphylococcus aureus / isolation & purification
Microbial Sensitivity Tests
Middle Aged
Staphylococcal Infections / drug therapy*
Staphylococcal Infections / microbiology
Treatment Outcome
Vancomycin / pharmacology
Vancomycin / therapeutic use*

Substances

Anti-Bacterial Agents
Cephalosporins
Vancomycin
Daptomycin